Monitor the Q1 FY2027 earnings release on August 13 for revenue, EPS, and any guidance updates. The conference call on August 14 may provide additional color on operations and pipeline. No immediate trading signal from this filing alone.
Price Chart
Executive Summary
Elite Pharmaceuticals filed an 8-K announcing that its Q1 FY2027 financial results will be released on August 13, 2026, followed by a conference call on August 14, 2026. No financial figures or guidance were disclosed in this filing — it is purely a scheduling announcement.
Key Facts
- Q1 FY2027 financial results to be released on August 13, 2026
- Conference call scheduled for August 14, 2026 at 11:30 AM EDT
- Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference ID 98840
- Stockholder questions due by August 12 (general) and August 13 (financial)
Financial Impact
No financial data disclosed in this filing
Risk Factors
- No financial data or guidance provided — results could disappoint
- OTCQB-listed stock with limited liquidity and coverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036905 |
| Exhibit: ex99-1.htm | 0001493152-26-036905 |
| Document: 0001493152-26-036905-index-headers.html | 0001493152-26-036905 |
| Document: 0001493152-26-036905-index.html | 0001493152-26-036905 |
| Document: 0001493152-26-036905.txt | 0001493152-26-036905 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3600 | awaiting T+60 | — | $0.2371 (−34.14%) |
Jun 29, 2026 17w ago | 8-K | $0.3700 $0.2470 | ▼ −33.24% | ▼ −37.08% | $0.2371 (−35.92%) |
Jun 15, 2026 19w ago | 8-K | $0.3700 $0.2599 | ▼ −29.76% | ▼ −31.02% | $0.2371 (−35.92%) |
Jun 1, 2026 21w ago | 8-K | $0.3600 $0.2827 | ▼ −21.47% | ▼ −22.70% | $0.2371 (−34.14%) |
Apr 2, 2026 29w ago | 8-K | $0.3800 $0.3651 | ▼ −3.92% | ▼ −18.08% | $0.2371 (−37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers